Skip to main content
. 2020 Aug 11;28(Suppl 1):115–121. doi: 10.1007/s12471-020-01449-3

Table 3.

Patient selection for referral to advanced heart failure centre using I NEED HELP

I Inotropics Previous or current need for inotropics
N NYHA III–IV/Natriuretic peptides Persisting NYHA III–IV or increased (NT-pro)BNP
E End-organ failure Deteriorating kidney and/or liver function
E Ejection fraction Severely depressed left ventricular function (ejection fraction <20%)
D Defibrillator shocks Repeated ICD shocks
H Hospitalisations More than 1 admission for heart failure in the last 12 months
E Edema or escalating diuretics Persisting congestion or increasing diuretic dose
L Low blood pressure Consistent low systolic blood pressure (<90–100 mm Hg)
P Prognostic medication Inability to titrate evidence based medication (ACE inhibitor/ARB/beta blocker/MRA or ARNI)

NYHA New York Heart Association, (NT-pro)BNP (N-terminal-pro) B‑type natriuretic peptide, ICD implantable cardioverter defibrillator, ACE angiotensin-converting enzyme, ARB angiotensin receptor blocker, MRA mineralocorticoid receptor antagonist, ARNI angiotensin receptor neprilysin inhibitor